Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Down 37.7% in September

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 66,800 shares, a drop of 37.7% from the September 15th total of 107,200 shares. Based on an average trading volume of 424,600 shares, the days-to-cover ratio is presently 0.2 days. Currently, 2.9% of the company’s stock are sold short. Currently, 2.9% of the company’s stock are sold short. Based on an average trading volume of 424,600 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

REVB has been the topic of a number of analyst reports. Wall Street Zen upgraded Revelation Biosciences to a “sell” rating in a report on Friday, June 27th. Weiss Ratings restated a “sell (e)” rating on shares of Revelation Biosciences in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Revelation Biosciences Price Performance

Shares of REVB stock opened at $1.25 on Wednesday. Revelation Biosciences has a 1-year low of $1.20 and a 1-year high of $60.48. The stock’s fifty day moving average price is $1.98 and its 200 day moving average price is $4.13. The company has a market cap of $2.93 million, a price-to-earnings ratio of -0.02 and a beta of -0.12.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($7.01) EPS for the quarter, missing analysts’ consensus estimates of ($4.46) by ($2.55). As a group, equities research analysts anticipate that Revelation Biosciences will post -49.33 earnings per share for the current year.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.